WilmerHale represented the joint-book running managers in the concurrent public offerings of (i) 7,400,000 shares of common stock of Xeris Pharmaceuticals, Inc. at a price to the public of $2.72 per share, for total gross proceeds to the Company of approximately $20.13 million (before underwriting discounts and expenses) and (ii) $75,000,000 aggregate principal amount of 5.00% convertible senior notes due 2025. In addition, Xeris granted the underwriters an option for a period of 30 days to purchase up to an additional 1,110,000 shares of common stock at the public offering price, less the underwriting discount and an additional $11,250,000 aggregate principal amount of notes, which the underwriters exercised in full. The transactions priced on June 25, 2020 and closed on June 30, 2020 and July 7, 2020.

The WilmerHale team consisted of Lisa Firenze, Glenn Pollner, Bruce Manheim, Colleen Superko, Chip McCorkle, Howell Ma, Jenny Moore and Heidi Treiber.